Biological effects and clinical characteristics of microRNA‑106a in human colorectal cancer

He,Yuzheng; Wang,Guiqi; Zhang,Lei; Zhai,Congjie; Zhang,Jun; Zhao,Xusheng; Jiang,Xia; Zhao,Zengren

doi:10.3892/ol.2017.6179

Biological effects and clinical characteristics of microRNA‑106a in human colorectal cancer

Authors:
- Yuzheng He
- Guiqi Wang
- Lei Zhang
- Congjie Zhai
- Jun Zhang
- Xusheng Zhao
- Xia Jiang
- Zengren Zhao
View Affiliations

Affiliations: Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China
Published online on: May 16, 2017 https://doi.org/10.3892/ol.2017.6179
Pages: 830-836
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs serve important roles in various diseases, particularly cancer. microRNA‑106a (miR‑106a) exhibits abnormal expression and oncogenic activity in carcinogenesis. The clinical significance of the abnormal expression of miR‑106a in colorectal cancer is poorly understood. In the present study, miR‑106a expression from colorectal cancer tissues was quantified using the reverse transcription‑quantitative polymerase chain reaction. The overexpression or knockdown of miR‑106a was performed by transfection with microRNA mimic or inhibitor in human colorectal carcinoma HCT116 cells. The overexpression of miR‑106a promoted viability and inhibited apoptosis in colorectal cancer cells. The association between miR‑106a expression and clinicopathological factors was analyzed, and it was identified that miR‑106a exhibited significantly increased expression in adenocarcinoma tissues compared with in mucinous carcinoma tissues, and the expression of miR‑106a was identified to be associated with the depth of invasion and differentiation. The expression of miR‑106a in plasma was also determined and it was identified that increased expression of miR‑106a, as a characteristic of patients with colorectal cancer, may be distinguished from that of other patients by digitization of the areas under the receiver operating characteristic curves. These data suggested that miR‑106a is a potential biomarker in the diagnosis of colorectal carcinoma. However, the underlying molecular mechanism of miR‑106a‑promoted viability and inhibition of apoptosis requires further investigation.

View Figures

View References

1	Wasserman M, Baxter NN, Rosen B, Burnstein M and Halverson AL: Systematic review of internet patient information on colorectal cancer surgery. Dis Colon Rectum. 57:64–69. 2014. View Article : Google Scholar : PubMed/NCBI
2	Yang W, Lee DY and Ben-David Y: The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 3:140–155. 2011.PubMed/NCBI
3	Hamaya Y, Yoshida K, Takai T, Ikuma M, Hishida A and Kanalka S: Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer. 102:916–921. 2010. View Article : Google Scholar : PubMed/NCBI
4	Mo ZH, Wu XD, Li S, Fei BY and Zhang B: Expression and clinical significance of microRNA-376a in colorectal cancer. Asian Pac J Cancer Prev. 15:9523–9527. 2014. View Article : Google Scholar : PubMed/NCBI
5	Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fawad-Kazan M, Badran R, Hamade E, Daher A, Hussein N, ElDirani R, et al: Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 11:312013. View Article : Google Scholar : PubMed/NCBI
6	Ye JJ and Cao J: MicroRNAs in colorectal cancer as markers and targets-Recent advances. World J Gastroenterol. 20:4288–4299. 2014. View Article : Google Scholar : PubMed/NCBI
7	Oglesby IK, McElvaney NG and Greene CM: MicroRNAs in inflammatory lung disease-master regulators or target practice? Respir Res. 11:1482010. View Article : Google Scholar : PubMed/NCBI
8	Holloway JW, Francis S Savarimuthu, Fong KM and Yang IA: Genomics and the respiratory effects of air pollution exposure. Respirology. 17:590–600. 2012. View Article : Google Scholar : PubMed/NCBI
9	Small EM and Olson EN: Pervasive roles of microRNAs in cardiovascular biology. Nature. 469:336–342. 2011. View Article : Google Scholar : PubMed/NCBI
10	Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafa R, Xiao L, Zhang X, Vannini I, Fanini F, et al: Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology. 142:886–896. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhou S, Ye W, Ren J, Shao Q, Qi Y, Liang J and Zhang M: MicroRNA-381 increases radiosensitivity in esophageal squamous cell carcinoma. Am J Cancer Res. 5:267–277. 2014.PubMed/NCBI
12	Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z, Chen Z, Qiu F, Xu J and Huang J: miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One. 8:e606872013. View Article : Google Scholar : PubMed/NCBI
13	Tong AW and Nemunaitis J: Modulation of miRNA activity in human cancer: A new paradigm for cancer gene therapy? Cancer Gene Ther. 15:341–355. 2008. View Article : Google Scholar : PubMed/NCBI
14	Xiao B, Guo J, Miao Y, Jiang Z, Huan R, Zhang Y, Li D and Zhong J: Detection of miR-106a in gastric carcinoma and its clinical significance. Clin Chim Acta. 400:97–102. 2009. View Article : Google Scholar : PubMed/NCBI
15	Xie X, Liu HT, Mei J, Ding FB, Xiao HB, Hu FQ, Hu R and Wang MS: miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. Int J Clin Exp Pathol. 8:3827–3834. 2015.PubMed/NCBI
16	Kim YW, Kim EY, Jeon D, Liu JL, Kim HS, Choi JW and Ahn WS: Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 8:293–314. 2014.PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Yu D, Zhang S, Du W, Zhang J, Fan Z, Hao H, Liu Y, Zhao X, Qin T and Zhu H: Expression of intracellular interferon-alpha confers antiviral properties in transfected bovine fetal fibroblasts and does not affect the full development of SCNT embryos. PLoS One. 9:e944442014. View Article : Google Scholar : PubMed/NCBI
19	Zhang L, Meng L, Fan Z, Liu B, Pei Y and Zhao Z: Expression of plasma miR-106a in colorectal cancer and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 34:354–357. 2014.(In Chinese). PubMed/NCBI
20	Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J and Xu N: miR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog. 52:634–646. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yuan R, Zhi Q, Zhao H, Han Y, Gao L, Wang B, Kou Z, Guo Z, He S, Xue X and Hu H: Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma. Tumour Biol. 36:3093–3100. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li P, Xu Q, Zhang D, Li X, Han L, Lei J, Duan W, Ma Q, Wu Z and Wang Z: Upregulated miR-106a plays an oncogenic role in pancreatic cancer. FEBS Lett. 588:705–712. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wang Z, Wang B, Shi Y, Xu C, Xiao HL, Ma LN, Xu SL, Yang L, Wang QL, Dang WQ, et al: Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene. 34:1407–1419. 2015. View Article : Google Scholar : PubMed/NCBI
24	Zhu M, Zhang N and He S: Similarly up-regulated microRNA-106a in matched formalin-fixed paraffin-embedded and fresh frozen samples and the dynamic changes during gastric carcinogenesis and development. Pathol Res Pract. 210:909–915. 2014. View Article : Google Scholar : PubMed/NCBI
25	Schee K, Boye K, Abrahamsen TW, Fodstad Ø and Flatmark K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 12:5052012. View Article : Google Scholar : PubMed/NCBI
26	Criscitiello C, Sotiriou C and Ignatiadis M: Circulating tumor cells and emerging blood biomarkers in breast cancer. Curr Opin Oncol. 22:552–558. 2010. View Article : Google Scholar : PubMed/NCBI
27	Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 6:e177452011. View Article : Google Scholar : PubMed/NCBI
28	Qin X, Xu H, Gong W and Deng W: The tumor cytosol miRNAs, fluid miRNAs, and exosome miRNAs in lung cancer. Front Oncol. 4:3572015. View Article : Google Scholar : PubMed/NCBI